Autologous blood transfusion inpatient with anemia using MAP solution and recombinant human erythropoietin.

使用 MAP 溶液和重组人促红细胞生成素对贫血患者进行自体输血。

• 批准号: 06671223
• 负责人: MAEDA Hiroo
• 金额: $ 1.28万
• 依托单位: Saitama Medical School
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1995
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-06671223/
• 关键词: Autologous blood donation; Cancer; Rheumatoid arthritis; Erythropoietin; エリスロポエチン

Autologous blood transfusion (ABT) is now widely used in the patients undergoing orthopedic or cardiovascular surgery to prevent adverse effects of homologous blood transfusion (HBT). However, Patients with cancer or with chronic inflammatory disease are frequently anemic at the time of operation, and therefore these patients are not likely to be candidates for autologous blood donation (ABD). In this study, we have undertaken ABD in these patients : 8 rheumatoid arthritis, 13gynecological cancer, and 8 gastrointestinal cancer : To safely perform ABD,200-300ml of autologous blood was collected in the patients with Hb less than 11.0g/dl, and 6,000IU of recombinant EPO was administered intravenously three times a week for two or three weeks. We safely collected 800-1,000 ml of autologous blood prior to operation from these patients who had been supposed to be difficult to donate autologous blood. rEPO was found as effective in the patients with gynecological cancer or rheumatoid patient with iron deficiency as in the patients in general good cnodition in term of the increase of Hb concentration after donation. In conclusion, we could safely colled autologous blood from the patients with anemia by reduction of volume of donation and by using rEPO during donation.

自体输血(ABT)现已广泛应用于骨科或心血管手术患者，以预防异体输血(HBT)的不良反应。然而，癌症或慢性炎症性疾病患者在手术时经常贫血，因此这些患者不太可能是自体献血(ABD)的对象。在本研究中，我们对8例类风湿性关节炎、13例妇科癌症和8例胃肠癌患者进行了ABD：为了安全地进行ABD，对Hb<11.0g/dl的患者采集200-300ml自体血，并每周3次静脉注射6000IU重组EPO，持续两到三周。我们在手术前安全地收集了800-1000毫升的自体血液，这些患者本来被认为很难捐献自体血液。根据献血后Hb浓度的升高，REPO对妇科癌症或类风湿缺铁的患者与一般情况良好的患者一样有效。综上所述，通过减少献血量和在献血时使用回购，可以安全地采集贫血患者的自体血液。

项目成果

前田平生: "整形外科領域における自己血輸血施行患者に対するエポエチンベータの臨床評価-皮下投与における後期第II相臨床試験" 薬学と新薬. 32. 119-135 (1995)

Hirao Maeda：“在骨科领域接受自体输血的患者中 β 型促红细胞生成素的临床评价 - 皮下给药的后期 II 期临床试验”《药理学和新药》32. 119-135 (1995)。

H.Maeda, et al: "Erythropoietin and autologous blood transfusion" Modern Physician. 14(3). 255-257 (1994)

H.Maeda 等人：“促红细胞生成素和自体输血”现代医师。

前田平生: "エリスロポエチンと自己血輸血" Modern Physician. 14. 255-257 (1994)

Hirao Maeda：“促红细胞生成素和自体输血”《现代医师》14. 255-257 (1994)。

前田平生: "整形外科手術と自己血輸血" メジカルビュー社, 190 (1995)

前田平雄：《骨科手术与自体输血》Medical View Publishing，190（1995）

H.Maeda, et al: "What is autologous blood transfusion?" Hematopoietic Factor. 5(suppl). 132-136 (1994)

H.Maeda 等人：“什么是自体输血？”